Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Federal Trade Commission
US Department of Justice
Dow
US Army
Cerilliant
McKinsey
Argus Health

Generated: May 27, 2018

DrugPatentWatch Database Preview

DYLOJECT Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Dyloject patents expire, and what generic alternatives are available?

Dyloject is a drug marketed by Javelin Pharms Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-four patent family members in eleven countries.

The generic ingredient in DYLOJECT is diclofenac sodium. There are forty-seven drug master file entries for this compound. Eighty-six suppliers are listed for this compound. Additional details are available on the diclofenac sodium profile page.
Drug patent expirations by year for DYLOJECT
Synonyms for DYLOJECT
(o-(2,6-Dichloroanilino)phenyl)acetic acid monosodium salt
(o-(2,6-Dichloroanilino)phenyl)acetic acid sodium salt
1147187-62-9
15307-79-6
2-((2,6-Dichlorophenyl)amino)benzeneacetic acid monosodium salt
2-(2,6-DICHLOROANILINO)PHENYLACETIC ACID SODIUM SA
2-(2,6-Dichloroanilino)phenylacetic Acid Sodium Salt
2-[(2,6-Dichlorophenyl)amino]-benzeneacetic acid monosodium salt
2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid sodium
2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid sodium salt
2-[(2,6-Dichlorophenyl)amino]benzeneacetic Acid, Na
A809387
AB0013319
AB1009344
Abitren
AC-1487
AC1NMYU1
AC1Q1V6Y
Acetic acid, o-(2,6-dichloroanilino)phenyl-, monosodium salt
AKOS000310014
AKOS005267222
AKOS024278942
Allvoran
AN-14916
Anthraxiton
API0002325
ARONIS24305
Assaren
Ba 47210
Batafil
BBC/461
BC201631
BCP0726000303
BCP9000605
Benfofen
Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)-, monosodium salt
Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, monosodium salt
Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, monosodium salt [CAS]
Berifen
BG0165
BIM-0051341.0001
Blesin
C14H10Cl2NNaO2
CAS-15307-79-6
CCG-100765
CCG-39754
CCRIS 1909
CHEBI:4509
CHEMBL1034
CPD000058567
CPD000449318
CS-2355
D 6899
D00904
D2508
Delimon
Delphimix
DIC075V
Dichronic
Diclofenac (Sodium)
Diclofenac sod
Diclofenac sodium
Diclofenac sodium (JP17/USP)
Diclofenac sodium [USAN:JAN]
Diclofenac sodium [USAN:USP:JAN]
Diclofenac Sodium 1.0 mg/ml in Methanol (as free acid)
Diclofenac sodium injection
Diclofenac sodium salt
Diclofenac sodium topical gel
Diclofenac-D4 (Major)
Diclophenac sodium
DSSTox_CID_17208
DSSTox_GSID_37208
DSSTox_RID_79308
DTXSID3037208
EC 239-346-4
Ecofenac
EINECS 239-346-4
EU-0100441
Feloran
FT-0624732
GP 45840
GP-45840
GP9539
H867
HMS1569H10
HMS1920E16
HMS2051M05
HMS2091M06
HMS2096H10
HMS2235O06
HMS2236D03
HMS3261I04
HMS3369K11
HMS3371J05
HMS3393M05
HMS3650B13
HMS3655A22
HMS500N14
HY-15037
I06-0162
I06-162
IN1491
K-4848
KPHWPUGNDIVLNH-UHFFFAOYSA-M
Kriplex
KS-00000KCZ
KS-000048IF
KS-5038
KSC-322-017
KUC112363N
Lopac-D-6899
LP00441
LS-11576
MCULE-3279769301
MFCD00082251
MLS000028386
MLS000758255
MLS001148587
MLS001423970
MLS002222163
MLS003882590
MolPort-000-699-119
NC00015
NCGC00015361-01
NCGC00015361-02
NCGC00015361-03
NCGC00015361-04
NCGC00017082-01
NCGC00017082-02
NCGC00017082-03
NCGC00021125-03
NCGC00093858-01
NCGC00093858-02
NCGC00094648-01
NCGC00094648-02
NCGC00253928-01
NCGC00261126-01
Neriodin
Olfen
Opera_ID_564
OR067148
OR114393
OR224831
Orthophen
Ortofen
potassium diclofenac(1-)
Prophenatin
Q-200965
QTG126297Q
REGID_for_CID_5018304
RL01959
s1903
SAM001247057
SBB032269
SC-25991
SCHEMBL24009
SMR000058567
SMR000449318
Sodium (2-((2,6-dichlorophenyl)amino)phenyl)acetate
Sodium (o-((2,6-dichlorophenyl)amino)phenyl)acetate
Sodium (o-(2,6-dichloroanilino)phenyl) acetate
Sodium (o-(2,6-dichloroanilino)phenyl)acetate
sodium {2-[(2,6-dichlorophenyl)amino]phenyl}acetate
sodium 2-(2-((2,6-dichlorophenyl)amino)phenyl)acetate
sodium 2-(2,6-dichloroanilino)-phenylacetate
Sodium 2-(2,6-Dichloroanilino)phenylacetate
sodium 2-[(2,6-dichlorophenyl)-amino]-phenyl-acetate
sodium 2-[(2,6-dichlorophenyl)-amino]-phenylacetate
sodium 2-[(2,6-dichlorophenyl)-amino]phenylacetate
sodium 2-[(2,6-dichlorophenyl)amino]phenylacetate
sodium 2-[2-(2,6-dichloroanilino)phenyl]acetate
Sodium 2-[2-[(2,6-Dichlorophenyl)amino]phenyl]acetate
sodium 2-[2-[[2,6-bis(chloranyl)phenyl]amino]phenyl]ethanoate
sodium 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetate
SODIUM DICHLOFENAC
Sodium diclofenac
sodium diclofenac(1-)
sodium;2-[2-(2,6-dichloroanilino)phenyl]acetate
Solaraze
Solaraze (TN)
SPECTRUM1500237
ST024738
STK400073
STOCK1S-60350
TDS 943
Tox21_110770
Tox21_110770_1
Tox21_300265
Tox21_500441
Tsudohmin
UNII-QTG126297Q
Urigon
Valetan
Voltaren
Voltaren (TN)
Voltaren Gel
Voltaren ophthalmic
Voltaren-XR
Voltarene
Vonafec
Vurdon
ZX-AS004665

US Patents and Regulatory Information for DYLOJECT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Javelin Pharms Inc DYLOJECT diclofenac sodium SOLUTION;INTRAVENOUS 022396-001 Dec 23, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Javelin Pharms Inc DYLOJECT diclofenac sodium SOLUTION;INTRAVENOUS 022396-001 Dec 23, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for DYLOJECT
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 37.5 mg/mL, 1 mL single-dose vials ➤ Subscribe 2015-12-15

Non-Orange Book US Patents for DYLOJECT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,580,954 Formulations of low dose diclofenac and beta-cyclodextrin ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Harvard Business School
Colorcon
Julphar
Argus Health
Covington
Moodys
Fuji
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.